IPM 036


Protocol Title: An Open-Label, Randomised, Three-Period Crossover Trial in Healthy HIV-Negative Women to Assess the Drug-Drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25mg of Dapivirine, and Clotrimazole 10 mg/g (1%) Administered as a Vaginal Cream


IPM 036 is an open-label, randomized, crossover Phase I clinical trial designed to assess the potential drug-drug interactions as well as the safety of co-administration of the dapivirine ring and vaginally administered clotrimazole, a drug commonly used to treat vaginal infections. Healthy, HIV-negative women participating in the trial are randomly assigned to one of three treatment sequences.

Participating Research Centers

  • SGS Life Science Services — Antwerp, Belgium

Publications, presentations or other scientific data

  • Van Niekerk et al. Pharmacokinetics (PK) of Dapivirine Vaginal Ring (25 mg) Co-administered With Clotrimazole [poster presentation]. HIV R4P Conference 2018. See abstract.